Key result
Hypertonic saline with furosemide linked to ~0.8-kg greater daily weight loss without worsening creatinine.
Why the study?
Does intravenous furosemide combined with hypertonic saline solution improve weight loss and prevent renal function deterioration in patients with acute decompensated heart failure?
Observational (n=47)
Open-label
No
Does intravenous furosemide combined with hypertonic saline solution improve weight loss and prevent renal function deterioration in patients with acute decompensated heart failure?
Answers are grounded in this paper and cite their sources.
Hypertonic saline combined with high-dose intravenous furosemide is an effective and renally safe strategy for weight loss in patients with acute decompensated heart failure who do not respond to conventional diuretic therapy.
AIM: To test the safety and effectiveness of hypertonic saline solution (HSS + F) as a strategy for weight loss and prevention of further deterioration of renal function. METHODS: Patients admitted with acute decompensated heart failure (ADHF) who received HSS + F were included in the study. After a period of a standard ADHF treatment, our patients received an intravenous infusion of furosemide (250 mg) combined with HSS (150 mL of 3% NaCl) twice a day for a mean duration of 2.3 d. Our primary outcomes were weight loss and a change in serum creatinine per day of treatment. The parameters of the period prior to treatment with HSS + F were compared with those of the period with HSS + F. Importantly, the change in creatinine was not significantly different. CONCLUSION: This study supports the effectiveness of HSS + F on weight loss in patients with ADHF. The safety profile, particularly with regard to renal function, leads us to believe that HSS + F may be a valuable option for those patients presenting with ADHF who do not respond to conventional treatment with intravenous furosemide alone.
No takes yet. Share an insight, caveat, or question.
Lafrenière et al. (2017) conducted an observational in Acute decompensated heart failure (n=47). Hypertonic saline solution plus intravenous furosemide (HSS + F) vs. Standard intravenous furosemide alone (prior treatment period) was evaluated on Weight loss per day of treatment (kg/d) (MD 0.80 kg/d, 95% CI 0.15, 1.44, p=0.0168). Hypertonic saline solution combined with IV furosemide increased daily weight loss compared to IV furosemide alone (-1.43 vs -0.39 kg/d; MD 0.80 kg/d, P=0.0168) without worsening serum creatinine.
Synapse has enriched 10 related papers. Consider them for comparative context: